TORONTO, October 7, 2019 – TerrAscend Corp. (CSE: TER; OTCQX: TRSSF) ("TerrAscend" or "the Company"), the first and only global cannabis company licensed for sales in Canada, the US, and the EU, today announced that it has received approval from Health Canada for significant expansion at its facility in Mississauga, Ontario.
This approval increases licensed space at the Mississauga facility nearly three-fold from 17,800 sq. ft. to 51,800 sq. ft., and includes additional cultivation capacity, a commercial kitchen, formulation rooms and increased primary and secondary packaging capacity to allow for new product formats and extracts for the Canadian Cannabis 2.0 market.
Achieving this approval milestone is a crucial step in our plan to cultivate premium grade cannabis at scale for distribution to the EU and other international markets. Michael Nashat, CEO of TerrAscend
Nashat went on to say that "in addition, our newly licensed processing operations pave the way for TerrAscend to meet the significant increased consumer demand expected upon the launch of Cannabis 2.0. Over the coming months, we plan on introducing the Canadian market to the proven brands and formulations from our US operations, as well as new proprietary dosage forms developed in our EU GMP certified Ontario-based facility."
First licensed for cultivation in July 2017, TerrAscend's 67,300 sq. ft. GMP certified indoor cannabis facility located in Mississauga, Ontario, is focused on serving the Canadian medical and adult-use markets, conducting research & development for plant sciences and formulations, and serving as a platform for export of cannabis products to Europe and other international jurisdictions.
The Canadian Securities Exchange ("CSE") has neither approved nor disapproved the contents of this news release. Neither the CSE nor its Market Regulator (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.
Disclaimer: Past performance is not an indicator of future performance.
Disclaimer: past performance is not an indicator of future performance.
TerrAscend provides quality products, brands, and services to the global cannabinoid market. As the first North American Operator (NAO), with scale operations in both Canada and the US, the Company participates in the medical and legal adult use market across Canada and in several US states where cannabis has been legalized for therapeutic or adult use. TerrAscend is the first and only cannabis company with sales in the US, Canada, and Europe as it has received EU GMP certification for its manufacturing facility in Mississauga, Ontario. TerrAscend operates a number of synergistic businesses, including The Apothecarium, an award-winning cannabis dispensary with several retail locations in California and Nevada; Arise Bioscience Inc., a manufacturer and distributor of hemp-derived products; Ilera Healthcare, Pennsylvania's premier medical marijuana cultivator, processor and dispenser; Ascendant Laboratories Inc., a biotechnology and licensing company committed to the continuous improvement of cannabinoid expressing plants; Solace RX Inc., a proposed Drug Preparation Premises (DPP) focused on the development of novel formulations and delivery forms; and Valhalla Confections, a manufacturer of premium cannabis-infused edibles. Additionally, TerrAscend has been chosen by the state of New Jersey to be one of six permit applicants for a vertically integrated medical cannabis operation
Get the Latest Marijuana News &
Content in your Inbox!
All your support helps The Green Fund keep writing content for all you
marijuana enthusiasts and potential pot stock investors